Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Keflex®, LY066873
Cephalexin · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cephalexin (Reference) | EXPERIMENTAL | Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods. |
| Cephalexin (Test) | ACTIVE_COMPARATOR | Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods. |
| Name | Type | Description |
|---|---|---|
| Cephalexin | DRUG | Administered orally |
Inclusion Criteria: * Participation will be voluntary. * The body mass index of participants should be between 18-27. * Participants should have a good health status. * Limits of variation allowed within normal values at screening will be: blood pressure (seated) up to 139 millimeters of mercury (m...
Cephalexin is a small molecule drug developed by Eli Lilly and Company. It has been studied in Phase 1 clinical trials involving healthy participants. The trials evaluated different formulations, including liquid, suspension, and capsules. Cephalexin is not approved for any indication based on the available data, and its development status remains investigational.
Cephalexin is developed by Eli Lilly and Company, which trades under the ticker symbol LLY. The company has sponsored multiple Phase 1 trials of the drug in Mexico, including studies of liquid, suspension, and capsule formulations in healthy volunteers.
Cephalexin is in Phase 1 clinical development. All five registered trials are Phase 1 studies, and they have been completed. The trials enrolled a total of 140 participants and were conducted in Mexico. No later-phase trials are listed, so the drug remains investigational.
Cephalexin has been studied in five completed Phase 1 trials, including NCT02490670, NCT02123472, NCT02123459, and NCT02123446. These trials evaluated liquid, suspension, and capsule formulations in healthy adult participants in Mexico. Each trial enrolled 28 participants, and all were active-controlled and randomized.
Cephalexin is not approved by the FDA for any indication based on the available data. It is an investigational drug that has completed Phase 1 clinical trials. The trials were conducted in Mexico and involved healthy volunteers, evaluating different oral formulations of the drug.